Travere Therapeutics, Inc. TVTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $536.2M+96.0% | $490.73M+110% | $435.83M+114% | $333.87M+87.9% | $273.53M+75.7% | ||
| $7.61M-30.3% | $10.34M+33.5% | $10.34M+6.0% | $10.38M+10.2% | $10.92M+24.0% | ||
| $528.59M+101% | $480.39M+113% | $425.49M+120% | $323.49M+92.3% | $262.61M+78.8% | ||
| 98.6%+2.6pp | 97.9%+1.2pp | 97.6%+2.4pp | 96.9%+2.2pp | 96%+1.7pp | ||
| $216.22M+0.6% | $206.01M-5.3% | $210.21M-2.3% | $210M-6.3% | $214.97M-9.0% | ||
| $344.62M+32.4% | $324.78M+23.0% | $292.58M+13.3% | $271.75M+4.4% | $260.31M-1.3% | ||
| $593.26M+18.5% | $553.55M-0.6% | $526.96M-6.0% | $506.08M-11.4% | $500.8M-14.5% | ||
| -$57.06M+74.9% | -$62.82M+80.6% | -$91.13M+74.5% | -$172.21M+56.3% | -$227.26M+47.1% | ||
| -10.6%+72.4pp | -12.8%+126pp | -20.9%+155pp | -51.6%+170pp | -83.1%+193pp | ||
| $10.19M-9.3% | $10.75M-3.9% | $11.27M+0.8% | $11.3M+0.6% | $11.24M-0.4% | ||
| $12.25M+819% | $13.55M+308% | $2.58M-70.1% | $3.11M-70.8% | $1.33M-90.9% | ||
| -$44.81M+80.2% | -$49.27M+84.6% | -$88.55M+74.6% | -$169.1M+55.9% | -$225.93M+45.6% | ||
| $829K— | $988K— | —— | —— | —— | ||
| —— | —— | -$88.54M+74.8% | -$169.06M-15.9% | -$226.71M-40.7% | ||
| —— | —— | -$1.04+77.1% | -$2.02-7.4% | -$2.79-32.9% | ||
| $16.09M+109% | -$2.08M+99.3% | -$36.43M+88.5% | -$122.06M+65.4% | -$180.79M+53.4% | ||
| 3%+69.1pp | -0.4%+120pp | -8.4%+147pp | -36.6%+162pp | -66.1%+183pp | ||
| -$57.06M+74.9% | -$62.82M+80.6% | -$91.13M+74.5% | -$172.21M+56.3% | -$227.26M+47.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Travere Therapeutics, Inc.'s profit margins?
- Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
- Where does Travere Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.